To better understand potential drivers that mediate sensitivity to MEK inhibition in BTC, we conducted a full comprehensive analysis utilizing whole exome sequencing to assess for tumor-specific variants in patients who experienced a response to selumetinib. Here, MAP2K7 is linked to neoplasm.